Medicines in this atlas
The drugs and medicine products this atlas holds that a registry trial names or that carry a regulatory decision, with how many of each. A trial counts for a medicine when its registry record names the medicine under a name this atlas holds for it, so the table does not list every medicine used in these conditions. (page 1 of 4)
-
- Type
- Drug
- Class
- Trials
- 116
- Phase 3 or 4
- 97
- Recruiting
- 25
- Regulatory decisions
- 0
- Sponsors
- 97
-
- Type
- Drug
- Class
- GLP-1 receptor agonists (drug class)
- Trials
- 116
- Phase 3 or 4
- 94
- Recruiting
- 20
- Regulatory decisions
- 0
- Sponsors
- 48
-
- Type
- Drug
- Class
- P2Y12 inhibitors (drug class)
- Trials
- 109
- Phase 3 or 4
- 91
- Recruiting
- 11
- Regulatory decisions
- 0
- Sponsors
- 89
-
- Type
- Drug
- Class
- Trials
- 94
- Phase 3 or 4
- 79
- Recruiting
- 24
- Regulatory decisions
- 0
- Sponsors
- 63
-
- Type
- Drug
- Class
- SGLT2 inhibitors (drug class)
- Trials
- 92
- Phase 3 or 4
- 82
- Recruiting
- 17
- Regulatory decisions
- 0
- Sponsors
- 54
-
- Type
- Drug
- Class
- Statins
- Trials
- 81
- Phase 3 or 4
- 64
- Recruiting
- 7
- Regulatory decisions
- 0
- Sponsors
- 57
-
- Type
- Drug
- Class
- Trials
- 79
- Phase 3 or 4
- 70
- Recruiting
- 9
- Regulatory decisions
- 0
- Sponsors
- 69
GLP-1 receptor agonists (drug class)
- Type
- Drug
- Class
- Trials
- 72
- Phase 3 or 4
- 57
- Recruiting
- 12
- Regulatory decisions
- 0
- Sponsors
- 33
-
- Type
- Drug
- Class
- Trials
- 72
- Phase 3 or 4
- 63
- Recruiting
- 4
- Regulatory decisions
- 0
- Sponsors
- 56
-
- Type
- Drug
- Class
- P2Y12 inhibitors (drug class)
- Trials
- 70
- Phase 3 or 4
- 59
- Recruiting
- 9
- Regulatory decisions
- 0
- Sponsors
- 57
-
- Type
- Drug
- Class
- SGLT2 inhibitors (drug class)
- Trials
- 67
- Phase 3 or 4
- 54
- Recruiting
- 15
- Regulatory decisions
- 0
- Sponsors
- 39
-
- Type
- Drug
- Class
- Statins
- Trials
- 59
- Phase 3 or 4
- 54
- Recruiting
- 3
- Regulatory decisions
- 0
- Sponsors
- 45
-
- Type
- Drug
- Class
- Trials
- 53
- Phase 3 or 4
- 45
- Recruiting
- 9
- Regulatory decisions
- 0
- Sponsors
- 43
-
- Type
- Drug
- Class
- Fibrinolytic (clot-dissolving) drugs
- Trials
- 51
- Phase 3 or 4
- 39
- Recruiting
- 18
- Regulatory decisions
- 0
- Sponsors
- 30
-
- Type
- Drug
- Class
- Trials
- 47
- Phase 3 or 4
- 39
- Recruiting
- 12
- Regulatory decisions
- 0
- Sponsors
- 36
-
- Type
- Drug
- Class
- PCSK9 inhibitors
- Trials
- 47
- Phase 3 or 4
- 38
- Recruiting
- 1
- Regulatory decisions
- 0
- Sponsors
- 17
-
- Type
- Drug
- Class
- Trials
- 46
- Phase 3 or 4
- 37
- Recruiting
- 9
- Regulatory decisions
- 0
- Sponsors
- 35
-
- Type
- Drug
- Class
- Trials
- 42
- Phase 3 or 4
- 37
- Recruiting
- 3
- Regulatory decisions
- 0
- Sponsors
- 19
-
- Type
- Drug
- Class
- GLP-1 receptor agonists (drug class)
- Trials
- 41
- Phase 3 or 4
- 34
- Recruiting
- 9
- Regulatory decisions
- 0
- Sponsors
- 16
-
- Type
- Drug
- Class
- Calcium channel blockers
- Trials
- 40
- Phase 3 or 4
- 30
- Recruiting
- 5
- Regulatory decisions
- 0
- Sponsors
- 30
-
- Type
- Drug
- Class
- Trials
- 33
- Phase 3 or 4
- 27
- Recruiting
- 4
- Regulatory decisions
- 0
- Sponsors
- 30
Fibrinolytic (clot-dissolving) drugs
- Type
- Drug
- Class
- Trials
- 32
- Phase 3 or 4
- 26
- Recruiting
- 16
- Regulatory decisions
- 0
- Sponsors
- 22
-
- Type
- Drug
- Class
- PCSK9 inhibitors
- Trials
- 28
- Phase 3 or 4
- 25
- Recruiting
- 1
- Regulatory decisions
- 0
- Sponsors
- 7
-
- Type
- Drug
- Class
- Trials
- 28
- Phase 3 or 4
- 24
- Recruiting
- 3
- Regulatory decisions
- 0
- Sponsors
- 22
-
- Type
- Drug
- Class
- P2Y12 inhibitors (drug class)
- Trials
- 27
- Phase 3 or 4
- 25
- Recruiting
- 2
- Regulatory decisions
- 0
- Sponsors
- 25
Sacubitril/valsartan (combination)
- Type
- Drug
- Class
- Trials
- 27
- Phase 3 or 4
- 21
- Recruiting
- 3
- Regulatory decisions
- 0
- Sponsors
- 10
-
- Type
- Drug
- Class
- Mineralocorticoid receptor antagonists (drug class)
- Trials
- 26
- Phase 3 or 4
- 22
- Recruiting
- 11
- Regulatory decisions
- 0
- Sponsors
- 13
-
- Type
- Drug
- Class
- Trials
- 26
- Phase 3 or 4
- 22
- Recruiting
- 3
- Regulatory decisions
- 0
- Sponsors
- 8
-
- Type
- Drug
- Class
- Angiotensin receptor blockers (ARBs)
- Trials
- 24
- Phase 3 or 4
- 21
- Recruiting
- 1
- Regulatory decisions
- 0
- Sponsors
- 16
-
- Type
- Drug
- Class
- Trials
- 23
- Phase 3 or 4
- 22
- Recruiting
- 2
- Regulatory decisions
- 0
- Sponsors
- 21
-
- Type
- Drug
- Class
- Angiotensin receptor blockers (ARBs)
- Trials
- 21
- Phase 3 or 4
- 14
- Recruiting
- 2
- Regulatory decisions
- 0
- Sponsors
- 19
-
- Type
- Drug
- Class
- Antiarrhythmic drugs
- Trials
- 20
- Phase 3 or 4
- 19
- Recruiting
- 3
- Regulatory decisions
- 0
- Sponsors
- 20
Mineralocorticoid receptor antagonists (drug class)
- Type
- Drug
- Class
- Trials
- 19
- Phase 3 or 4
- 16
- Recruiting
- 6
- Regulatory decisions
- 0
- Sponsors
- 9
-
- Type
- Drug
- Class
- Trials
- 18
- Phase 3 or 4
- 14
- Recruiting
- 1
- Regulatory decisions
- 0
- Sponsors
- 13
-
- Type
- Drug
- Class
- Trials
- 16
- Phase 3 or 4
- 10
- Recruiting
- 1
- Regulatory decisions
- 0
- Sponsors
- 15
-
- Type
- Drug
- Class
- Heparins and low-molecular-weight heparins
- Trials
- 16
- Phase 3 or 4
- 16
- Recruiting
- 1
- Regulatory decisions
- 0
- Sponsors
- 15
-
- Type
- Drug
- Class
- Thiazide and thiazide-like diuretics
- Trials
- 16
- Phase 3 or 4
- 12
- Recruiting
- 0
- Regulatory decisions
- 0
- Sponsors
- 14
-
- Type
- Drug
- Class
- Beta-blockers (drug class)
- Trials
- 15
- Phase 3 or 4
- 13
- Recruiting
- 1
- Regulatory decisions
- 0
- Sponsors
- 12
-
- Type
- Drug
- Class
- ACE inhibitors
- Trials
- 15
- Phase 3 or 4
- 13
- Recruiting
- 0
- Regulatory decisions
- 0
- Sponsors
- 7
-
- Type
- Drug
- Class
- Fibrinolytic (clot-dissolving) drugs
- Trials
- 14
- Phase 3 or 4
- 12
- Recruiting
- 0
- Regulatory decisions
- 0
- Sponsors
- 10
Angiotensin receptor blockers (ARBs)
- Type
- Drug
- Class
- Trials
- 14
- Phase 3 or 4
- 11
- Recruiting
- 3
- Regulatory decisions
- 0
- Sponsors
- 14
-
- Type
- Drug
- Class
- Anticoagulants
- Trials
- 13
- Phase 3 or 4
- 13
- Recruiting
- 0
- Regulatory decisions
- 0
- Sponsors
- 11
-
- Type
- Drug
- Class
- Trials
- 13
- Phase 3 or 4
- 12
- Recruiting
- 0
- Regulatory decisions
- 0
- Sponsors
- 13
Heparins and low-molecular-weight heparins
- Type
- Drug
- Class
- Anticoagulants
- Trials
- 13
- Phase 3 or 4
- 11
- Recruiting
- 0
- Regulatory decisions
- 0
- Sponsors
- 13
-
- Type
- Drug
- Class
- Angiotensin receptor blockers (ARBs)
- Trials
- 13
- Phase 3 or 4
- 9
- Recruiting
- 0
- Regulatory decisions
- 0
- Sponsors
- 8
-
- Type
- Drug
- Class
- Trials
- 12
- Phase 3 or 4
- 11
- Recruiting
- 3
- Regulatory decisions
- 0
- Sponsors
- 6
-
- Type
- Drug
- Class
- Trials
- 11
- Phase 3 or 4
- 10
- Recruiting
- 1
- Regulatory decisions
- 0
- Sponsors
- 9
-
- Type
- Drug
- Class
- Beta-blockers (drug class)
- Trials
- 11
- Phase 3 or 4
- 9
- Recruiting
- 1
- Regulatory decisions
- 0
- Sponsors
- 11
-
- Type
- Drug
- Class
- Statins
- Trials
- 11
- Phase 3 or 4
- 8
- Recruiting
- 0
- Regulatory decisions
- 0
- Sponsors
- 8
-
- Type
- Drug
- Class
- Angiotensin receptor blockers (ARBs)
- Trials
- 11
- Phase 3 or 4
- 9
- Recruiting
- 0
- Regulatory decisions
- 0
- Sponsors
- 8
-
- Type
- Drug
- Class
- Beta-blockers (drug class)
- Trials
- 10
- Phase 3 or 4
- 10
- Recruiting
- 3
- Regulatory decisions
- 0
- Sponsors
- 10
-
- Type
- Drug
- Class
- Calcium channel blockers
- Trials
- 9
- Phase 3 or 4
- 9
- Recruiting
- 1
- Regulatory decisions
- 0
- Sponsors
- 7
-
- Type
- Drug
- Class
- Angiotensin receptor blockers (ARBs)
- Trials
- 8
- Phase 3 or 4
- 5
- Recruiting
- 1
- Regulatory decisions
- 0
- Sponsors
- 8
-
- Type
- Drug
- Class
- Trials
- 8
- Phase 3 or 4
- 8
- Recruiting
- 3
- Regulatory decisions
- 0
- Sponsors
- 8
-
- Type
- Drug
- Class
- Statins
- Trials
- 8
- Phase 3 or 4
- 8
- Recruiting
- 0
- Regulatory decisions
- 0
- Sponsors
- 8
-
- Type
- Drug
- Class
- Trials
- 7
- Phase 3 or 4
- 6
- Recruiting
- 0
- Regulatory decisions
- 0
- Sponsors
- 4
-
- Type
- Drug
- Class
- Calcium channel blockers
- Trials
- 6
- Phase 3 or 4
- 5
- Recruiting
- 0
- Regulatory decisions
- 0
- Sponsors
- 6
-
- Type
- Drug
- Class
- ACE inhibitors
- Trials
- 6
- Phase 3 or 4
- 5
- Recruiting
- 0
- Regulatory decisions
- 0
- Sponsors
- 6
-
- Type
- Drug
- Class
- Beta-blockers (drug class)
- Trials
- 6
- Phase 3 or 4
- 5
- Recruiting
- 1
- Regulatory decisions
- 0
- Sponsors
- 5
-
- Type
- Drug
- Class
- Beta-blockers (drug class)
- Trials
- 5
- Phase 3 or 4
- 4
- Recruiting
- 0
- Regulatory decisions
- 0
- Sponsors
- 5
-
- Type
- Drug
- Class
- Thiazide and thiazide-like diuretics
- Trials
- 5
- Phase 3 or 4
- 4
- Recruiting
- 0
- Regulatory decisions
- 0
- Sponsors
- 5
-
- Type
- Product
- Class
- Trials
- 5
- Phase 3 or 4
- 5
- Recruiting
- 1
- Regulatory decisions
- 9
- Sponsors
- 4
-
- Type
- Drug
- Class
- ACE inhibitors
- Trials
- 5
- Phase 3 or 4
- 4
- Recruiting
- 1
- Regulatory decisions
- 0
- Sponsors
- 5
Thiazide and thiazide-like diuretics
- Type
- Drug
- Class
- Trials
- 5
- Phase 3 or 4
- 4
- Recruiting
- 0
- Regulatory decisions
- 0
- Sponsors
- 5
-
- Type
- Drug
- Class
- Inotropes and vasopressors
- Trials
- 4
- Phase 3 or 4
- 3
- Recruiting
- 1
- Regulatory decisions
- 0
- Sponsors
- 3
-
- Type
- Drug
- Class
- Omega-3 fatty acid drugs
- Trials
- 4
- Phase 3 or 4
- 2
- Recruiting
- 0
- Regulatory decisions
- 0
- Sponsors
- 4
-
- Type
- Drug
- Class
- Statins
- Trials
- 4
- Phase 3 or 4
- 4
- Recruiting
- 0
- Regulatory decisions
- 0
- Sponsors
- 4
-
- Type
- Drug
- Class
- Thiazide and thiazide-like diuretics
- Trials
- 3
- Phase 3 or 4
- 2
- Recruiting
- 0
- Regulatory decisions
- 0
- Sponsors
- 3
Semaglutide injection for diabetes (Ozempic)
- Type
- Product
- Class
- Trials
- 3
- Phase 3 or 4
- 3
- Recruiting
- 0
- Regulatory decisions
- 4
- Sponsors
- 3
-
- Type
- Drug
- Class
- Calcium channel blockers
- Trials
- 3
- Phase 3 or 4
- 2
- Recruiting
- 1
- Regulatory decisions
- 0
- Sponsors
- 3
-
- Type
- Product
- Class
- Trials
- 2
- Phase 3 or 4
- 2
- Recruiting
- 0
- Regulatory decisions
- 5
- Sponsors
- 2
-
- Type
- Drug
- Class
- Inotropes and vasopressors
- Trials
- 2
- Phase 3 or 4
- 2
- Recruiting
- 1
- Regulatory decisions
- 0
- Sponsors
- 1
-
- Type
- Product
- Class
- Trials
- 2
- Phase 3 or 4
- 2
- Recruiting
- 0
- Regulatory decisions
- 5
- Sponsors
- 2
Semaglutide injection for weight management (Wegovy)
- Type
- Product
- Class
- Trials
- 2
- Phase 3 or 4
- 2
- Recruiting
- 0
- Regulatory decisions
- 8
- Sponsors
- 2
-
- Type
- Drug
- Class
- Transthyretin stabilizers and transthyretin-directed RNA interaction medicines
- Trials
- 2
- Phase 3 or 4
- 2
- Recruiting
- 0
- Regulatory decisions
- 0
- Sponsors
- 1
-
- Type
- Drug
- Class
- Trials
- 1
- Phase 3 or 4
- 1
- Recruiting
- 0
- Regulatory decisions
- 0
- Sponsors
- 1
-
- Type
- Drug
- Class
- Trials
- 1
- Phase 3 or 4
- 1
- Recruiting
- 0
- Regulatory decisions
- 0
- Sponsors
- 1
Direct oral anticoagulants (DOACs)
- Type
- Drug
- Class
- Anticoagulants
- Trials
- 1
- Phase 3 or 4
- 1
- Recruiting
- 1
- Regulatory decisions
- 0
- Sponsors
- 1
-
- Type
- Product
- Class
- Trials
- 1
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 10
- Sponsors
- 1
-
- Type
- Product
- Class
- Trials
- 1
- Phase 3 or 4
- 1
- Recruiting
- 0
- Regulatory decisions
- 7
- Sponsors
- 1
-
- Type
- Product
- Class
- Trials
- 1
- Phase 3 or 4
- 0
- Recruiting
- 1
- Regulatory decisions
- 4
- Sponsors
- 1
-
- Type
- Product
- Class
- Trials
- 1
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 4
- Sponsors
- 1
-
- Type
- Drug
- Class
- Inotropes and vasopressors
- Trials
- 1
- Phase 3 or 4
- 1
- Recruiting
- 1
- Regulatory decisions
- 0
- Sponsors
- 1
-
- Type
- Drug
- Class
- Beta-blockers (drug class)
- Trials
- 1
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 0
- Sponsors
- 1
-
- Type
- Product
- Class
- Trials
- 1
- Phase 3 or 4
- 1
- Recruiting
- 0
- Regulatory decisions
- 4
- Sponsors
- 1
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 3
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 3
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 1
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 6
- Sponsors
- 0
-
- Type
- Product
- Class
- Trials
- 0
- Phase 3 or 4
- 0
- Recruiting
- 0
- Regulatory decisions
- 5
- Sponsors
- 0